MDM2 and melanoma: Although the HDM2 antagonist MI-319 failed to induce an increase in PI-staining, AIF nuclear translocation, or any other manifestation of programmed cell death in melanoma cells when used as a single agent, it was markedly toxic in some (e.g. A375), but not all, melanoma cell lines when used in conjunction with the multikinase inhibitor sorafenib.